IQVIA Holdings Inc. $IQV Stock Sold by Philadelphia Trust Co.

Philadelphia Trust Co. decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 5.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 86,779 shares of the medical research company’s stock after selling 5,154 shares during the quarter. IQVIA accounts for approximately 1.5% of Philadelphia Trust Co.’s portfolio, making the stock its 19th largest position. Philadelphia Trust Co.’s holdings in IQVIA were worth $23,331,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Korea Investment CORP bought a new stake in IQVIA during the 2nd quarter worth about $13,918,000. Congress Asset Management Co. bought a new position in shares of IQVIA in the third quarter worth about $24,560,000. National Pension Service raised its stake in shares of IQVIA by 6.6% in the second quarter. National Pension Service now owns 375,973 shares of the medical research company’s stock worth $72,646,000 after acquiring an additional 23,411 shares during the last quarter. Deutsche Bank AG acquired a new position in shares of IQVIA during the second quarter worth approximately $143,074,000. Finally, BlackRock Inc. acquired a new position in shares of IQVIA during the second quarter worth approximately $2,811,292,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

IQVIA stock opened at $275.44 on Wednesday. The company has a market cap of $45.39 billion, a PE ratio of 33.47, a PEG ratio of 2.48 and a beta of 1.16. The company has a current ratio of 0.83, a quick ratio of 0.83 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $284.50. The company’s 50-day moving average is $267.20 and its two-hundred day moving average is $211.40.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, October 27th. The medical research company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.26 by $0.08. The company had revenue of $4.43 billion during the quarter, compared to analysts’ expectations of $4.37 billion. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. IQVIA’s revenue was up 8.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.00 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 11.53 earnings per share for the current year.

Insider Buying and Selling

In other IQVIA news, insider James G. Berkshire sold 2,668 shares of IQVIA stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares of the company’s stock, valued at approximately $2,845,883.70. The trade was a 19.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on IQV shares. Leerink Partners raised their price target on shares of IQVIA from $280.00 to $310.00 and gave the company an “outperform” rating in a report on Thursday, October 8th. HSBC boosted their price objective on shares of IQVIA from $280.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, September 1st. BMO Capital Markets upped their price objective on IQVIA from $270.00 to $305.00 in a report on Monday, October 19th. Barclays increased their price objective on IQVIA from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Finally, Jefferies Financial Group lifted their target price on IQVIA from $220.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $294.21.

IQVIA Profile

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.